Table 1.
Baseline characteristics of randomized patients
| Overall (n = 24) | Gla300‐Deg (n = 12) | Deg‐Gla300 (n = 12) | P‐value | |
|---|---|---|---|---|
| Age (years) | 70.7 ± 7.6 | 69.5 ± 9.5 | 71.9 ± 5.2 | 0.447 |
| Duration of diabetes (years) | 14.0 ± 9.3 | 11.6 ± 9.1 | 16.5 ± 9.1 | 0.199 |
| Male, n (%) | 12 (50.0) | 5 (41.7) | 7 (58.3) | 0.436 |
| BMI (kg/m2) | 23.1 ± 3.3 | 24.0 ± 2.4 | 22.3 ± 3.6 | 0.179 |
| HbA1c (%) | 6.80 ± 0.35 | 6.78 ± 0.33 | 6.83 ± 0.34 | 0.780 |
| S‐CPR (ng/mL) | 1.1 ± 0.6 | 1.3 ± 0.7 | 0.9 ± 0.4 | 0.057 |
| Basal insulin dosage (U) | 6.0 ± 3.0 | 5.9 ± 2.5 | 6.2 ± 3.5 | 0.843 |
| Antidiabetic agents | ||||
| DPP4 inhibitor (n) | 20 | 10 | 10 | 0.500 |
| Metformin (n) | 11 | 7 | 4 | 0.313 |
| SGLT2 inhibitor (n) | 6 | 4 | 2 | 0.394 |
| Sulfonylurea (n) | 1 | 1 | 0 | 0.322 |
| Glinides (n) | 16 | 7 | 9 | 0.550 |
| α‐GI | 14 | 5 | 9 | 0.212 |
Values are expressed as mean ± standard deviation. α‐GI, alpha‐glucosidase inhibitor; BMI, body mass index; Deg, insulin degludec U100; DPP4, dipeptidyl peptidase‐4; Gla300, insulin glargine 300 U/mL; HbA1c, glycated hemoglobin; S‐CPR, serum C‐peptide; SGLT2, sodium–glucose cotransporter 2.